Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2020-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary of the audit opinion, key financial data, and auditor information for Ensol Biosciences. While it contains financial data, it is a regulatory filing announcing the submission of the audit report to the exchange, rather than the full annual report itself. Given the structure and content, it falls under the category of Audit Report / Information. FY 2019
2020-03-19 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Ensol Biosciences. It contains the meeting agenda, date, location, and detailed management information regarding board activities, director remuneration, and business operations (business overview, industry status, and R&D pipeline). This document is a formal proxy statement/notice sent to shareholders to inform them of the upcoming meeting and provide necessary background information for voting. In the context of the provided categories, this fits best as a Proxy Solicitation & Information Statement (PSI).
2020-03-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by Ensol Biosciences. It outlines the date, location, and agenda items for the upcoming meeting, including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2020-03-06 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the reasoning for this scheduling choice and provides relevant dates. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, proxy statements, or voting results, it falls under the general regulatory filing category.
2020-03-06 Korean
기타주요경영사항(자율공시)(동물용 골관절염치료제 품목 허가 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure (자율공시) regarding the approval of a new animal drug (JointVex) by the Animal and Plant Quarantine Agency. It details the product, its efficacy, and the approval date. Since it is a specific regulatory announcement regarding company operations and product approval that does not fit into financial reporting or specific corporate action categories like M&A or dividends, it is classified as a general regulatory filing.
2020-02-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This document details the personal share transactions (insider trading) of a company executive (Lee Tai Au) of Ensol Biosciences. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2019-12-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.